Evidence map›Paper›PMID 21434848›Full record

ArticleAIDS research and human retroviruses2011

Effects of stabilization of the gp41 cytoplasmic domain on fusion activity and infectivity of SIVmac239.

Andrei N Vzorov, Richard W Compans

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andrei N VzorovDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Richard W Compans
Emory University · US

Funding

Design of HIV VLPs with Enhanced ImmunogenicityR01AI090840 · NIAID · EMORY UNIVERSITY · PI COMPANS, RICHARD W · 2010 to 2013
$1.9M
NIAID NIH HHS AI090840NIAID NIH HHS R01 AI090840
6 · The paper itself

Abstract

We investigated the effects of introducing specific sequences that are predicted to affect trimer stability into the CT domain of the SIV Env protein. Two constructs, 3HBai and 3HBaa, with additional GCN4-related sequences in the CT domain (45 aa) had enhanced infectivity, and differed in their fusion activity and trimer stability. Another construct, 3HBii, exhibited a very stable trimeric structure. Pseudotyped virions containing 3HBii retained infectivity despite the lack of syncytia formation. In contrast, 3HBai and 3HBaa, which caused extensive syncytia formation, had a less stable trimeric structure. We observed an inverse correlation between trimer stability and fusion activity but no correlation between syncytia formation activity and infectivity. Quantitative cell-cell fusion assays, analysis of Env incorporation, measurement of ectodomain conformation by CD4 binding, and CCR5 blocking assays indicated differential effects on fusion activity and infectivity of the viruses with Env CT modifications. Differences in interaction with CD4 were not affected by trimer stability and were not related to fusion activity or infectivity. The results indicate that changes in the stability of the CT domain can have significant effects on functional activities of the Env external domain and can impact viral biological properties.

Indexed as

Cell FusionAmino Acid SequenceAnimalsCD4 AntigensCell LineGenes, envHIV Envelope Protein gp41HumansMembrane FusionMiceMutationNIH 3T3 CellsProtein Structure, TertiaryReceptors, CCR5Simian Immunodeficiency VirusVirionCD4 AntigensHIV Envelope Protein gp41Receptors, CCR5

Identifiers

PMID21434848
PMCPMC3206742
OpenAlexW2055431523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.